Provision Language
<p><span style=”text–decoration: underline;”><b>14. Extension of Expiration Date; Terminationb>span>p>
<p><span style=”font–weight: 400;”><strong>14.2strong> Without affecting any other right or remedy available to it, either Party may terminate the Supply Agreement with immediate effect by giving written notice to the other Party if: span>p>
<p style=”padding–left: 25px;”><span style=”font–weight: 400;”>(a) the other Party commits a material breach of any term of the Supply Agreement which breach is irremediable or if such breach is remediable fails to remedy that breach within a period of thirty (30) days after being notified to do so; span>p>
<p style=”padding–left: 25px;”><span style=”font–weight: 400;”>(b) the other Party takes any step or action in connection with its entering administration, provisional liquidation or any composition or arrangement with its creditors (other than in relation to a solvent restructuring), being wound up (whether voluntarily or by order of the court, unless for the purpose of a solvent restructuring), having a receiver appointed to any of its assets or ceasing to carry on business or, if the step or action is taken in another jurisdiction, in connection with any analogous procedure in the relevant jurisdiction; span>p>
<p style=”padding–left: 25px;”><span style=”font–weight: 400;”>(c) the other Party suspends, or threatens to suspend, or ceases or threatens to cease to carry on all or a substantial part of its business; span>p>
<p style=”padding–left: 25px;”><span style=”font–weight: 400;”>(d) the other Party or any of its directors, employees, or consultants have been found to have violated any applicable Anti–Corruption Laws.span>p>
<p><span style=”font–weight: 400;”>14.3 Customer has the right to terminate the Supply Agreement upon thirty (30) days’ written notice to Dynavax in the event: span>p>
<p style=”padding–left: 25px;”><span style=”font–weight: 400;”>(a) there is a significant efficacy or safety concern related to the Customer Product(s) or the Dynavax Adjuvant or the Customer Vaccine that cannot be resolved to a Regulatory Authority’s satisfaction; orspan>p>
<p style=”padding–left: 25px;”><span style=”font–weight: 400;”>(b) a <a href=”#kt“>Regulatory Authoritya> directs that the Customer Product(s) / Customer Vaccine / Dynavax Adjuvant be recalled or removed from the market; span>p>
<p style=”padding–left: 25px;”><span style=”font–weight: 400;”>(c) Customer Product(s) / Customer Vaccine do not receive the necessary <a href=”#kt“>Regulatory Approvala>(s) for the development, manufacturing or commercialization; or span>p>
<p style=”padding–left: 25px;”><span style=”font–weight: 400;”>(d) for any other reason including for convenience;span>p>
<p><span style=”font–weight: 400;”>in each case, subject to the provisions of <span style=”text–decoration: underline;”><a href=”https://ghiaa.org/provision_document/biological–e–dynavax–technologies–covid–19–vaccine–adjuvant–supply–agreement–11/” target=”_blank” rel=”noopener“>Section 15a>span>.span>p>
